Clinical Trial Update: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

View source ↗

Summary

A retrospective analysis examines second-line therapies used after progression on a CDK4/6 inhibitor plus hormonal therapy in patients with HR-positive, HER2-ne…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Snippet

Sponsor: University of Milano Bicocca | Conditions: Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma | Status: COMPLETED